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Abstract.Metabolites can be an important read-out of disease. The identification and
validation of biomarkers in the cancer metabolome that can stratify high-risk patients
is one of the main current research aspects. Mass spectrometry has become the
technique of choice for metabolomics studies, andmass spectrometry imaging (MSI)
enables their visualization in patient tissues. In this study, we used MSI to identify
prognostic metabolite biomarkers in high grade sarcomas; 33 high grade sarcoma
patients, comprising osteosarcoma, leiomyosarcoma, myxofibrosarcoma, and undif-
ferentiated pleomorphic sarcoma were analyzed. Metabolite MSI data were obtained
from sections of fresh frozen tissue specimens with matrix-assisted laser/desorption
ionization (MALDI) MSI in negative polarity using 9-aminoarcridine as matrix. Sub-
sequent annotation of tumor regions by expert pathologists resulted in tumor-specific metabolite signatures,
which were then tested for association with patient survival. Metabolite signals with significant clinical value were
further validated and identified by high mass resolution Fourier transform ion cyclotron resonance (FTICR) MSI.
Three metabolite signals were found to correlate with overall survival (m/z 180.9436 and 241.0118) and
metastasis-free survival (m/z 160.8417). FTICR-MSI identified m/z 241.0118 as inositol cyclic phosphate and
m/z 160.8417 as carnitine.
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Introduction
Soft tissue sarcomas are a rare group of tumors, comprisingless than 1% of all malignant tumors [1] with more than 50
histologic subtypes [2]. About 10% of patients with soft tissue
sarcoma have detectable metastases (most common in the
lungs) at diagnosis of the primary tumor, and at least one-
third of patients die from tumor-related disease (most of them
from lung metastases) [1]. Additionally, different tumor sub-
populations can have different clinical-pathological behavior
[3–5].
The combination of rarity, many subtypes with overlapping
and heterogeneous histologies, and molecular intratumor het-
erogeneity have made the correct diagnosis and treatment of
high-grade sarcomas challenging. Different therapeutic strate-
gies have been developed but the choice is dependent on
subtype because they confer different chemosensitivity [6].
Accurate histologic classification of sarcomas can be far from
straightforward: full concordance between primary diagnosis
and second opinion was observed in less than 60% [7]. Addi-
tionally, prognostic factors associated with local failure and
overall survival are also dependent on tumor location and size
[1]. There is an urgent need for more objective molecular
predictors to improve prognosis and treatment.
A cell’s metabolome has been defined as the unique chem-
ical fingerprints left behind by a cell’s specific molecular
process [8], and altered metabolism is now one of the hallmarks
of cancer [9]. Cancer cells can exhibit significant alterations in
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metabolic pathways such as glycolysis, respiration, the tricar-
boxylic acid cycle, oxidative phosphorylation, lipid metabo-
lism, and amino acid metabolism [10]. Tumors show various
metabolic aberrations but perhaps the most central to tumor
proliferation is the ‘Warburg effect’ [11]. Cancer cells repro-
gram their energy metabolism by limiting energy metabolism
to glycolysis, producing excessive levels of lactate, even under
normoxic conditions (Baerobic glycolysis^). The high rate of
glucose uptake and glycolysis in tumors is the basis for the
widely used tumor imaging technique [18F] deoxyglucose-
positron emission tomography (18FDG PET) [12–14].
The molecular basis for increased glycolysis and altered
metabolism is currently an active area of onco-metabolomic
research, and spans the identification and validation of bio-
markers in the cancer metabolome that can stratify high-risk
patients and/or distinguish between benign and advanced met-
astatic forms of the disease to the functional consequences of
the altered metabolic states [15, 16].
Previous studies on sarcoma-metabolomics has mostly con-
cerned cell lines [17–19] because of the much greater ease of
freezing their metabolome status; the metabolome reacts quick-
ly to changes in oxygen, blood supply, etc. Nevertheless, it is
important to assess metabolites within the histopathologic con-
text of patient tumor samples, especially so for histologically
heterogeneous tumors such as sarcomas.
Mass spectrometry imaging (MSI) has had a rapid and
substantial impact on clinical research [20] because of its
ability to directly visualize a tissue’s molecular content without
any labeling or a-priori knowledge [21–23]. MSI enables,
through a seamless integration of histology with the MSI data,
cell-type specific molecular signatures to be obtained from the
real histopathologic context of patient tissues [24, 25]. Both
matrix assisted laser desorption/ionization (MALDI) and de-
sorption electrospray ionization (DESI) have been used to
acquire metabolite MSI datasets of cancer tissues. For example
MALDI MSI may be used to visualize metabolites and meta-
bolic pathways in fresh frozen tumor tissues [26] and identify
biomarkers, including in formalin fixed paraffin embedded
tissues and tissue microarrays [27]; DESI has been used to
identify metabolite biomarkers for discriminating between dif-
ferent brain and breast tumors [28, 29]. Combining tumor-
specific metabolite signatures with patient follow-up data has
revealed prognostic biomarkers [27]. Though less established
for clinical research than protein MSI, these studies indicate
that the metabolite signatures obtained via MSI can also be
used to differentiate between different tumor entities and be-
tween patient groups.
MSI has previously been applied in sarcomas. Caldwell
et al. used MALDI MSI to investigate protein changes in the
tumor microenvironment of malignant fibrous histiocytoma
[30]. MALDI MSI of proteins has revealed molecular intra-
tumor heterogeneity in myxofibrosarcoma [5], and it has been
used to determine proteins and lipids that are tumor type- and
tumor grade-specific for myxoid liposarcoma and
myxofibrosarcoma [4]. However, an assessment of the prog-
nostic value of metabolites for soft tissue sarcomas has not
been reported to date. In this study, we investigated if the
metabolite and lipid signatures detected by MALDI MSI using
9-aminoacridine in high-grade sarcomas, including high-grade
leiomyosarcoma, myxofibrosarcoma, undifferentiated pleo-
morphic sarcoma, and osteosarcoma, can be associated with
patient prognosis.
Experimental
Tissue Specimens and Sample Cohorts
Fresh frozen tumor samples of high-grade myxofibrosarcoma
(MFS), leiomyosarcoma (LMS), undifferentiated pleomorphic
sarcoma (UPS), and osteosarcoma (OS) were collected and
handled as described previously [3]. Briefly, tissue samples
were obtained from the archive of the Department of
Pathology of Leiden University Medical Center (LUMC),
The Netherlands. All tumor samples were acquired during
routine patient care and were handled in a coded manner
according to the ethical guidelines described in BCode for
Proper Secondary Use of Human Tissue in The Netherlands^
of the Dutch Federation of Medical Scientific Societies. Slides
were reevaluated histologically and classified according to the
2013World Health Organization criteria. MFS and LMS cases
were histologically graded according to the French Fédération
Nationale des Centres de Lutte Contre le Cancer. The final
cohort comprised 8 LMS, 10 MFS, 8 UPS, and 7 OS patients
(ntotal = 33). Table 1 shows the clinic-pathological data of the
patient series.
Tissue Preparation
A semi-supervised block randomization was used to distribute
the patient tissue sections between and within slides in order to
minimize any potential sources of bias during MSI data acqui-
sition (pseudo-code available in Carreira et al. [31]).
Twelve micron-thick sections were cut at –20 °C in a
cryostat and thaw-mounted onto indium-tin-oxide glass slides
(Bruker Daltonik, Bremen, Germany) that had previously been
coated with poly-L-lysine [32]. The mounted tissue sections
were stored at –80 °C until use. Slides were first dried in a
freeze dryer for 15 min, then fiducial markers added near the
tissues using a Tipp-Ex pen. Tissue sections were sprayed with
10 mg/mL 9-aminoacridine in 70% methanol using the
ImagePrep spraying device (Bruker Daltonik). The spraying
method consisted of 22 cycles of 0.1 V for matrix layer thick-
ness at 20% power and 10% modulation with 1.5 s for nebu-
lization, 10 s of incubation, and 30 s of drying. Prior to the MSI
data acquisition the matrix-coated slides were placed in the
MSI slide holder and scanned with 2400 dpi resolution (Epson
V200 Photo). Note the resolution of the scanned image was
much higher than that of the MSI data (100 μm pixel size
corresponds to 254 dpi) to enable accurate co-registration with
the histological image.
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MSI Data Acquisition
All MSI experiments were performed using an Ultraflextreme
III MALDI-ToF/ToF mass spectrometer (Bruker Daltonik)
with a lateral resolution of 100 μm, a laser focus setting of
Blarge^ (corresponding to an on-target laser spot size of ap-
proximately 80 μm), and 500 accumulated laser shots per pixel
(10 laser shots per step of a random walk within each pixel).
Negatively charged ions up to m/z 1000 were detected with a
digitization rate of 4 GHz in reflectron mode. All pixel mass
spectra were processed with a smoothing algorithm (Savitzky-
Golay algorithm, width 0.005 m/z, two cycles) and a back-
ground subtraction (TopHat algorithm) during data acquisition
using FlexAnalysis (ver. 3.4; Bruker Daltonik).
After MSI data acquisition, the slides were washed in 70%
ethanol to remove the remaining matrix and then stained with
hematoxylin and eosin (H&E). High-resolution digital images
of the H&E stained tissues were then recorded using a
Pannoramic MIDI slide scanner (3DHISTECH Ld., Budapest,
Hungary) and co-registered to the MSI datasets in FlexImaging
3.0 (Bruker Daltonik).
Histological Annotation and MSI Data Quality
Control
The H&E stained images were histologically annotated by
expert pathologists. To ensure only comparable regions of
tissue were used in the subsequent statistical analysis, tumor
regions were classified according to their degree of differenti-
ation (well-, moderately-, or undifferentiated). These annotated
regions-of-interest (ROIs) were then used to extract the tumor-
specific metabolic signatures from the MSI data.
The quality of the MSI data from each ROI was then
evaluated in ClinProTools 3.0 (Bruker Daltonik) by using the
mass spectral preprocessing settings as reported in Supplemen-
tary Table 1: any dataset in which ≥40% of the spectra were
excluded by ClinProTools’ built-in quality control metrics
(either being non-alignable or a null spectrum) was disqualified
for the further analysis. Note: owing to the strong presence of
background peaks in the lower mass region, all ions up to m/z
range 100 were excluded from the analysis.
MSI Data Processing
The spectra from the annotated tumor areas of datasets that
passed all quality filters embracing sample selection based on
tumor cell fraction, MSI spectral quality assessment, and tissue
integrity after H&E (Supplementary Table 2), were loaded into
MATLAB R2013a (MathWorks, Natick, MA, USA) for fur-
ther processing (all settings are summarized in Supplementary
Table 3). There all spectra were normalized to their total-ion-
count (TIC), and pixels with the 1% lowest and 1% highest
TICs were discarded. Then a conservative peak picking using
the LIMPIC package was performed on each sample’s average
spectrum upon baseline removal (TopHat) and smoothing
(Kaiser) [33]. Frequent peaks, which appear in over 98% of
all samples, were used for recalibration of all spectra using the
msalign routine (Bioinformatics toolbox) in MATLAB. After
alignment, all tumor areas of the same differentiation degree
were aggregated for each sample into basepeak mass spectra
[34]. In a next step, all basepeak spectra were averaged across
all samples to obtain the global basepeak mass spectrum in
which metabolite peaks were detected by themspeaks function
(Bioinformatics toolbox; MATLAB) with a minimum relative
basepeak intensity threshold of 0.4%. This final project-
specific peak list was then used to extract the areas-under-the-
curve (AUC) values from the average spectra of each patient’s
tumor areas in two ways: first, to get the overall tumor profile
for each patient, and second, to get the overall profile for each
tumor differentiation degree for each patient.
Statistical Association of Metabolic Signals
to Survival of Patients
The association ofMSI signals of all subsets with the follow-up
data was investigated similarly as in our previous study of
protein biomarkers of soft tissue sarcomas [3] in R (R Founda-
tion for Statistical Computing, Vienna, Austria). Briefly, sig-
nificant relationships between peak intensities and the overall/
metastasis-free survival were first screened by using the Sig-
nificance Analysis of Microarrays analysis in R (SAMR pack-
age). Metabolite ions with significant prognostic value (q ≤
0.05; minimum median FDR) were then used to dichotomize
Table 1. Clinic-Pathological Characteristics of the Patient Series
High grade
leiomyosarcoma




No. of patients 8 10 8 7
Gender Male versus female 4 versus 4 3 versus 7 6 versus 2 4 versus 3
Age Median (y) 60.1 74.0 69.5 21.0
Therapy Neoadjuvant treatment 1 / 8 0 / 10 1 / 8 5/ 7
Adjuvant treatment 7 / 8 6 / 10 5 / 8 6 / 7
Length of follow-up Median overall survival (mo) 25.3 64% survival probability at max.




10.2 73% metastasis-free probability
at max. follow-up time (52.0
mo)
11.1 9.5
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patients based on the third quartile of intensity (data distribu-
tion and cutoff for onemass shown in Supplementary Figure 1).
Differences in the overall/metastasis-free survival between the
two resulting groups were compared by Kaplan-Meier curves
and the log rank test using the survival package. P-values
≤0.05 were considered significant.
Metabolite Identification Using High Mass Accu-
racy MALDI-FTICR
Additional tissue sections were prepared from patients whose
MALDI-TOF-based MSI datasets contained the prognostic
metabolite ions in high abundance (see above description).
These tissue sections were then analyzed using an ultrahigh
mass resolution mass spectrometer, namely a 9.4T MALDI
Solarix XR Fourier transform ion cyclotron resonance mass
spectrometer equipped with a dynamically harmonized
ParaCell (Bruker Daltonik, Bremen, Germany). MSI was per-
formed in negative mode using 500 laser shots per spot, laser
frequency 1 kHz, and 100 μm pixel size. Data was acquired
from m/z 50 to 1000 with a 512 k data point transient and an
estimated resolution of 19,000 at m/z 400 Da. Data acquisition
was performed using ftmsControl (Bruker Daltonik).
Metabolite identities were assigned on the basis of accurate
mass and matched isotope distributions measured with a high
field FTICR MS. The metabolites measured with the FTICR
were assigned to peaks measured with the MALDI-TOF sys-
tem on the basis of accurate mass, isotope patterns, and used
matched spatial distributions as an additional constraint.
Results and Discussion
Here we investigated whether MSI could identify metabolite
biomarkers associated with survival and metastasis in high
grade sarcomas. Prognostic metabolite signals were first iden-
tified based on MALDI-ToF-MSI data, then confirmed and
identities assigned using high resolution, high mass accuracy
MALDI-FTICR-MSI.
High grade sarcomas can be highly heterogeneous histolog-
ically, with a single tumor containing areas of different histo-
logic grade, necrotic regions, and a variable inflammatory cell
infiltrate. This heterogeneity can introduce high measurement
variance, complicating the search for molecular biomarkers [3].
Therefore, a histopathology-defined data analysis approach
was utilized in which each tissue’s histology was first annotat-
ed by pathologists who specialized in soft tissue sarcomas.
Each tissue section was first analyzed by MALDI MSI and
then H&E stained. High resolution histologic images were
recorded using a digital slide scanner, which were then regis-
tered to the MSI datasets using fiducial markers in
FlexImaging. A virtual microdissection was then performed
to isolate the mass spectra from designated tumor regions of
interest. In this manner, the spectra from areas with comparable
histologic grade (well differentiated, moderately differentiated,
undifferentiated), free of inflammatory cell infiltrate, free of
necrosis, and with high tumor cell content were extracted from
each patient tissue. This cell-specific data was used for the
statistical analysis. The workflow is depicted in Figure 1.
To control false positive identification of biomarkers, we
used three sequential filters:
(1) A Significance Analysis of Microarrays (SAM) [35] was
used to screen for survival-associated peaks. SAM controls
the false positive identification rate and was set here to 5%.
(2) A log rank test on the dichotomized patient survival data
was used to confirm the prognostic capability of the me-
tabolite peaks.
(3) Metabolite biomarker ions identified only detected in small
groups of patients, less than 10, were omitted.
The clinical covariates (Table 1) did not exhibit any signif-
icant association to the patient survival data (age, gender, tumor
type, adjuvant therapy; in all case the log-rank test resulted with
P > 0.05), or the clinical covariate was significant but defined
groups of too small sample size (e.g., only two neoadjuvantly
treated patients) that a reliable statistical analysis could not be
guaranteed. Similarly, the prognostic biomarkers were not
significantly associated with the clinical covariates.
The analysis revealed three metabolite ions that were sig-
nificantly associated to patient survival in sarcoma patients:m/z
180.90 (P = 0.006) and m/z 240.88 (P = 0.022), both indicative
of a poor overall survival in soft tissue sarcoma patients; and
m/z 160.81 (P = 0.017) indicative of a poor metastasis-free
survival in myxofibrosarcoma patients. The Kaplan-Meier
plots are shown in Figure 2. In order to increase the sample
size for the subgroups, leiomyosarcoma, myxofibrosarcoma,
and undifferentiated pleomorphic sarcoma were grouped to-
gether as a single non-osteosarcoma (non-OS) group because
these three subtypes are all soft tissue sarcomas, whereas
osteosarcoma is primarily located in bone. Common bio-
markers are beneficial from both a clinical and logistical view-
point: for rare and sometimes diagnostically challenging tu-
mors such as high grade sarcomas, which only present 1% of
all malignancies and have over 50 histologic subtypes, a prog-
nostic biomarker common to many/all subtypes would be more
broadly applicable, even for cases in which a definitive diag-
nosis is uncertain.
The prognostic value of the metabolite ions were confirmed
by visualizing the metabolite MSI data in patient samples with
good and poor survival. Figure 3 shows the differential detec-
tion level of the metabolite ion at m/z 180.90 in two non-OS
patients with differential survival.
The metabolite MALDI MSI datasets used for the statistical
analysis were obtained using a MALDI-TOF mass spectrome-
ter. The mass accuracy and mass resolution of the system does
not allow for the unambiguous assignment of the prognostic
metabolite ions. Several poor survival and good survival pa-
tient tissues were re-analyzed using a high field FTICR mass
spectrometer, in order to obtain high mass resolution high mass
accuracy MALDI MSI data. Despite significant differences in
mass analyzer technology (the time scale of detection of the
MALDI-TOF instrument is approximately 105 times shorter
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than that of the FTICR) the mass spectral patterns were con-
sistent, Supplementary Figure 4. As an example, the MS im-
ages fromMALDI-TOF andMALDI-FTICR form/z 241.0118
are shown in Figure 4. The mass accuracy of the FTICR
experiments was obtained using the metabolites ATP, ADP,
and AMP (images and experimental masses reported in Sup-
plementary Figure 2), and was found to be less than 3 ppm
(note: the MSI dataset was not aligned nor recalibrated).
Accordingly, 3 ppm was the used for the maximum mass
tolerance for querying metabolomics databases.
It is now well established that MALDI MSI, using a given
matrix preparation, detects a consistent subset of metabolites.
Metabolite identities were assigned on the basis of accurate
mass, and matched isotope distributions measured with a high
field FTICR system to previously reported metabolite ions.
MS/MS was attempted but the low signal intensities of the
Figure 1. Study workflow. (1) Fresh frozen tissues with diagnosis of leiomyosarcoma, myxofibrosarcoma, undifferentiated pleo-
morphic sarcoma, and osteosarcoma were collected and revised by pathologists in LUMC. (2) Tissue samples were cryosectioned
and the matrix 9-arminoarcridine applied. (3) MALDI-MSI datasets were acquired using a MALDI-TOF platform and spectra from
regions of interest were extracted for analysis. (4) Datasets QC and inclusion criteria (full criteria listed in Supplementary Table 2). (5)
Spectra from all the datasets were processed in MATLAB including sample alignment. (6) Masses that showed significant
relationship between peak intensity and survival time were first selected using Bsignificance analysis of microarrays,^ then were
analyzed using Kaplan-Meier survival analysis, and finally were evaluated to ensure biomarkers were independently correlated with
the survival time. (7) Representative poor and good survival patient samples were measured using a MALDI-FTICR platform for high
accuracy. (8) Significant masses with high accuracy were assigned based on human metabolome database and using isotope
patterns as an additional constraint
Figure 2. Kaplan-Meier survival plots of prognostic biomarkers discovered fromMALDI-TOF MSI datasets. Prognostic metabolite
ions were found from a sub-dataset of myxofibrosarcomas and from a dataset consisting of all soft tissue sarcomas (non-OS
subset). (a) Shows a metabolite ion (m/z 240.88) that was found when the analysis was limited to undifferentiated areas, and was
indicative for poor survival of soft tissue sarcoma patients; (b) and (c) show two metabolite ions (m/z 180.90 and m/z 160.84)
indicating poor survival in soft tissue sarcoma patients and myxofibrosarcoma patients, respectively. P-values listed are calculated
using a log-rank test in Kaplan-Meier analysis
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metabolite peaks and the presence of isobaric ions (see Sup-
plementary Figure 3) led to very noisy MS/MS spectra.
Within 2 ppm difference, the molecule atm/z 160.8417 was
previously reported by Buck et al. at m/z 160.8420 in colon
Figure 3. MALDI-TOF MSI data of the prognostic metabolite ion atm/z 180.90. (a) Shows a comparison of the average spectra of
two soft tissue sarcoma samples, one with good prognosis (blue line) and one with poor prognosis (red line); (b) shows the
magnification ofm/z 180.90. Histologic images and MSI visualizations for these two samples are shown in (c), confirming the higher
detected intensity throughout the poor survival patient sample
Figure 4. Comparison of MALDI MSI images recorded using the MALDI-TOF and MALDI-FTICR mass spectrometers. Histologic
images of four samples are shown in (a)–(d); (e)–(h) are theMS images of inositol cyclic phosphate obtained with theMALDI-FTICR,
and (i)–(l) the MS images obtained with the MALDI-TOF instrument
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cancer and assigned as carnitine [27]. Themolecule observed at
m/z 241.0118 was assigned as inositol cyclic phosphate using
the Human Metabolome Database with an error of 0.32 ppm
and matching the isotope pattern (Supplementary Figure 3).
The ion detected at m/z 180.9436 could not be assigned using
the available databases and MALDI-MSI literature. Here we
detected the abundant metabolites that were statistically asso-
ciated to patient survival. Metabolites signals that could differ-
entiate between the different histologic subtypes were also
assessed, but none were statistically significant.
Carnitine is an amino acid derivate involved in lipid metab-
olism and is known to contribute tomultiple diseases, including
cancer [36]. Carnitine plays an essential role in transporting
fatty acids to mitochondria with the help of carnitine palmitoyl
transferase I (CPTI) for energy production by fatty acid oxida-
tion (FAO) [37]. FAO and CPTI have been reported as emerg-
ing therapeutic targets in cancer [38]. Inositol (1,2-)cyclic
phosphate belongs to the class of organic compounds known
as cyclitols. It can be transformed to inositol 1-phosphate (IP),
which is involved in inositol 1,4,5-trisphosphate and calcium
(IP3/Ca2+) signaling system [39]. Altered expression of inosi-
tol IP3 receptor has been reported in different types of cancer
and implicated in patient prognosis [40, 41].
The prognostic metabolite biomarker inositol cyclic phos-
phate was found to be statistically significant only when the
analysis was focused on the undifferentiated regions of soft
tissue sarcoma samples. Undifferentiated tumor cells are
abnormal-looking cells compared with moderately differenti-
ated or well differentiated tumor cells, and are considered to be
more malignant. The increased statistical significance observed
when the analysis was focused on undifferentiated tumor areas
is consistent with molecular and/or measurement variance be-
ing introduced by histologic heterogeneity; the increased vari-
ance in the measured data undermines the ability to obtain
statistically significant results.
The work reported here could be expanded in several dif-
ferent directions: (1) validate the results in a larger independent
series; (2) assess whether inositol (1,2-)cyclic phosphate and
carnitine are also prognostic for additional subtypes of soft-
tissue sarcoma; (3) investigate the biological foundations of
their prognostic value, which may ultimately lead to novel
treatment strategies [42].
Sample degradation can be a very important issue in meta-
bolomics research, and several methods have been investigated
for maintaining metabolic integrity of tissue samples for
MALDI MSI [43, 44]. If the purpose of the study is to inves-
tigate metabolic processes, metabolic integrity is key. Main-
taining metabolic integrity is a major challenge for clinical
tissue samples, as those obtained via resection (the majority
of those that are available) will have undergone degradation
during surgery as blood vessels are sealed, especially consid-
ering it has previously been shown that post-mortem degrada-
tion occurs more rapidly at body temperature than at room
temperature [45]. The more limited scope of a biomarker study,
in which the goal is to find mass spectral features that differ-
entiate between patient groups, in this instance between poor
and good survival, does not require maintenance of the sys-
tem’s original metabolic state, only that the mass spectral
features consistently differentiate between the groups. This
work and previous work using MALDI of FFPE tissues [27],
and DESI based analyses [28, 29], have clearly demonstrated
the utility of metabolic signatures for differentiating between
patient groups. For clinical research in which metabolic integ-
rity needs to be kept as close as possible to the original
physiologic state flash frozen needle biopsies are
recommended.
Conclusions
A prognostic metabolite biomarker discovery platform was
setup for histologically heterogeneous high-grade sarcomas
using fresh frozen tumor tissues. Inositol cyclic phosphate
and carnitine were found to be potential generic prognostic
biomarkers in soft tissue sarcoma patients.
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